{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:05:16Z","timestamp":1789715116151,"version":"4.0.1"},"reference-count":41,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p> Purpose: To determine the response rate and toxicity of flavopiridol in patients with previously untreated or relapsed mantle-cell lymphoma. <\/jats:p><jats:p> Patients and Methods: Adult patients with previously untreated or in first or second relapse of previously responsive mantle-cell lymphoma were given flavopiridol 50 mg\/m<jats:sup>2<\/jats:sup>\/d by intravenous bolus for 3 consecutive days every 21 days with antidiarrheal prophylaxis. Flavopiridol was continued until disease progression, unacceptable toxicity, or stable disease for four cycles. Disease was reassessed every two cycles. <\/jats:p><jats:p> Results: From 33 registered patients, 30 were eligible after pathology review, 30 were assessable for toxicity, and 28 were assessable for response. A median of four cycles of treatment was administered; 90% of patients received at least 90% of planned dose-intensity. No complete responses were seen; three patients had a partial response (11%), 20 patients had stable disease (71%), and five patients had progressive disease (18%). The median duration of response was 3.3 months (range, 2.8 to 13.2 months). The most common toxicities were diarrhea (97%), fatigue (73%), nausea (47%), and vomiting (27%). At least one nonhematologic grade 3 or 4 toxicity was seen in 14 patients (47%). Hematologic toxicity was modest. <\/jats:p><jats:p> Conclusions: Flavopiridol given as a daily bolus for 3 consecutive days every 3 weeks has modest activity as a single agent for mantle-cell lymphoma. The number of stable and partial responses that was seen indicates that it is biologically active and may delay progression. Future studies in mantle-cell lymphoma should test this agent with other active agents and using different schedules. <\/jats:p>","DOI":"10.1200\/jco.2003.09.057","type":"journal-article","created":{"date-parts":[[2003,4,29]],"date-time":"2003-04-29T20:58:41Z","timestamp":1051649921000},"page":"1740-1745","source":"Crossref","is-referenced-by-count":177,"title":["Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group"],"prefix":"10.1200","volume":"21","author":[{"given":"C. Tom","family":"Kouroukis","sequence":"first","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crump","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Meyer","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Lohmann","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lopez","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Powers","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Turner","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"From the Hamilton Regional Cancer Centre, Hamilton; Princess Margaret Hospital, Toronto; National Cancer Institute of Canada, Clinical Trials Group, Queen\u2019s University, Kingston; London Regional Cancer Centre, London; Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario; Cross Cancer Institute, Edmonton, Alberta; and British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070505"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810915)48:6<1415::AID-CNCR2820480625>3.0.CO;2-N"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.9.742"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199207000-00001"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.7.2715.2715"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1038\/315340a0"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1126\/science.6610211"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.11.2819"},{"key":"R15","first-page":"3","volume":"6","year":"1996","journal-title":"Adv Leuk Lymphoma"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10056-9"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401994"},{"key":"R21","first-page":"2973","volume":"56","year":"1996","journal-title":"Cancer Res"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B"},{"key":"R23","first-page":"959","volume":"19","year":"1999","journal-title":"Anticancer Res"},{"key":"R24","first-page":"5433","volume":"59","year":"1999","journal-title":"Cancer Res"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.11.4307"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.393"},{"key":"R28","first-page":"4856","volume":"56","year":"1996","journal-title":"Cancer Res"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00103-5"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.458"},{"key":"R31","first-page":"2482","volume":"91","year":"1998","journal-title":"Blood"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2986"},{"key":"R33","first-page":"204a","volume":"19","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.2307\/2530297"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290016908"},{"key":"R38","first-page":"294b","volume":"96","year":"2000","journal-title":"Blood"},{"key":"R39","first-page":"2527","volume":"7","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R40","first-page":"1876","volume":"5","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R41","first-page":"4209","volume":"7","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R42","first-page":"3375","volume":"57","year":"1997","journal-title":"Cancer Res"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.080"},{"key":"R45","first-page":"3754S","volume":"5","year":"1999","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.09.057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:23:25Z","timestamp":1653819805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.09.057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5,1]]}},"alternative-id":["10.1200\/JCO.2003.09.057"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.09.057","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}